![]() |
|
|
Vol. 303, Issue 2, 497-502, November 2002
Laboratory of Cerebral Metabolism, National Institute of Mental Health (T.E., Y.I., M.C., J.J., L.S.), and The Positron Emission Tomography Department, Clinical Center (K.S.), National Institutes of Health, Bethesda, Maryland
| |
Abstract |
|---|
|
|
|---|
Local cerebral blood flow (CBF) was determined in 30 cerebral structures, including four structures of the whisker-to-barrel cortex sensory pathway, by the quantitative autoradiographic [14C]iodoantipyrine method during unilateral vibrissal stimulation in rats administered 0.1 or 1.0 mg/kg haloperidol or its control vehicle intravenously. The low dose of haloperidol had no significant effects on resting CBF or its enhancement by vibrissal stimulation. By standard t tests, the high dose statistically significantly lowered baseline CBF in frontal and visual cortex, hippocampus, dentate gyrus, inferior olive, cerebellar cortex, and the ventral posteromedial (VPM) thalamic nucleus on the unstimulated side, and raised baseline CBF in the lateral habenula; however, these changes lost statistical significance after Bonferroni correction for multiple comparisons. Neither dose had any effects on the increases in CBF evoked by vibrissal stimulation in the principal sensory trigeminal nucleus and barrel cortex, but the higher dose statistically significantly enhanced the percent increases in CBF due to the sensory stimulation in the spinal trigeminal nucleus and VPM thalamic nucleus. These results do not support a role for direct dopaminergic vasoactive mechanisms in the increases in CBF associated with neuronal functional activation.
| |
Introduction |
|---|
|
|
|---|
Dopamine
is a major neurotransmitter in brain that is released at synapses
located mainly in the striatum, a number of areas of the cerebral
cortex, and cortical and subcortical structures of the limbic system.
Dopamine or dopamine agonists have been shown in vitro and in vivo to
have vasoactive effects on blood vessels and to produce
vasoconstriction or vasodilatation, depending on the vascular bed and
dose. Vasodilatation is seen in renal, mesenteric, coronary, and
cerebral blood vessels, and because it is inhibited by dopaminergic
antagonists, it is probably mediated by specific dopamine receptors
(Goldberg, 1972
, 1975
; von Essen and Roos, 1974
; Toda, 1976
; Boullin et
al., 1977
; Edvinsson et al., 1977
, 1978
; McCulloch and Harper, 1977
).
Dopamine has vasoconstrictor effects in most vascular beds, including
that of the brain, but because the vasoconstriction is blocked not by
dopamine receptor antagonists but rather by
-adrenergic and
serotonin receptor antagonists, it is believed to be mediated by
-adrenergic and serotonin receptors (Goldberg, 1975
; Boullin et al.,
1977
; Edvinsson et al., 1977
, 1978
; von Essen et al., 1980
; Lacombe and
MacKenzie, 1997
).
Dopamine receptor subtypes were recently localized by immunoreactivity
in the smooth muscle of pial vessels (Amenta et al., 2000
), and
innervation of the intraparenchymal microvasculature by dopaminergic
axons was demonstrated by light and electron microscopic immunocytochemistry in dopamine-rich regions of the frontal cortex (Krimer et al., 1998
). Furthermore, perivascular application of dopamine in cortical brain slices in vitro was found to produce concentration-dependent vasoconstriction of the microvessels (Krimer et
al., 1998
). These observations led to the hypothesis that dopaminergic innervation of cortical blood vessels might play an important role in
the regulation of cerebral blood flow (CBF) and in the mechanism of the
enhancement of CBF by neuronal functional activation (Krimer et al.,
1998
). To examine this possibility directly, we have measured local CBF
in vivo in unanesthetized rats and determined the effects of dopamine
receptor blockade on baseline CBF and on its enhancement in four
stations of the whisker-to-barrel cortex sensory pathway evoked by
vibrissal stimulation.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals
4-Iodo[N-methyl-14C]antipyrine ([14C]antipyrine; [14C]IAP) (specific activity, 54 mCi/mmol) was purchased from PerkinElmer Life Sciences (Boston, MA). Haloperidol was purchased from Sigma-Aldrich (St. Louis, MO).
Animals
Normal, adult, male Sprague-Dawley rats (330-450g) were purchased from Charles River Laboratories (Wilmington, MA) and maintained in a climate-controlled room on a normal 12-h light/dark cycle, with food and water available ad libitum. Four groups of rats were studied, two treated with different doses of haloperidol and two corresponding control groups. The group that received the lower dose of haloperidol was infused intravenously over a 5-min period with 0.1 mg/kg haloperidol dissolved in physiological saline and adjusted to pH 4.0; a second group that served as controls for this lower dose was administered an equivalent infusion of the saline solution alone. The third was similarly infused but with 1.0 mg/kg haloperidol dissolved in physiological saline that had been adjusted to pH 2.8, and the fourth group, which served as controls for the group with the higher dose, was infused with comparable amounts of physiological saline at the same pH. The lower pH was required to dissolve the higher concentration of haloperidol.
Procedures
All procedures performed on animals were in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the local Animal Care and Use Committee.
Preparation of Animals.
The rats were anesthetized with
halothane (5% for induction and 1.0-1.5% for maintenance) in 70%
N2O/30% O2. Polyethylene catheters (PE 50; Clay-Adams, Parsippany, NJ) were inserted into the
left femoral vein and both femoral arteries. The venous catheter was
used for injection of drugs and infusion of the
[14C]iodoantipyrine. One arterial catheter was
used for continuous monitoring of mean arterial blood pressure,
whereas the other was used for sampling of arterial blood. The length
of the sampling catheter was fixed at precisely 16 cm to facilitate
correction for the effects of catheter delay and dead-space washout.
After insertion of the catheters, the surgical wounds were sutured and treated with 5% lidocaine ointment. After completion of the surgical procedure, a loose-fitting plaster cast was applied to the pelvic area
and taped to a lead brick to prevent locomotion. Because the
whisker-to-barrel cortex pathway was to be functionally activated unilaterally by vibrissal stimulation only on the left side, the whiskers on the right side of the face were cut close to the skin to
minimize the possibility of spurious stimulation of vibrissae on the
unstimulated control side. Unilateral stroking of whiskers in rats has
been shown to produce selective unilateral increases in local CBF in at
least four stations of the pathway, i.e., the ipsilateral spinal and
principal trigeminal nuclei and the contralateral ventral posteromedial
(VPM) nucleus of the thalamus and barrel region of the sensory cortex
(Ginsberg et al., 1987
; Adachi et al., 1994
).
Monitoring of Physiological Variables. Following the surgical preparation, several physiological variables that could influence CBF were monitored before and during the experimentally induced conditions. Mean arterial blood pressure was measured with a blood pressure analyzer (model 300; Digi-Med, Louisville, KY) that had been calibrated with an air-damped mercury manometer. Arterial blood pCO2, pO2, and pH were measured with a blood-gas analyzer (model 288 Blood Gas System; Ciba-Corning Diagnostics Corp., Medfield, MA). Arterial plasma glucose concentration was determined in a Beckman Glucose Analyzer 2 (Beckman Coulter, Inc., Fullerton, CA).
Determination of Cerebral Blood Flow.
Measurement of local
CBF was initiated at least 3 h after recovery from the anesthesia,
30 min after the infusion of the 0.1-mg/kg dose of haloperidol or its
vehicle, and 4 h after the infusion of the 1.0-mg/kg dose or its
vehicle. The longer time following the higher dose or its vehicle was
required for recovery from the transient acidosis caused by the lower
pH of the solution. Local CBF was determined by the quantitative
autoradiographic [14C]iodoantipyrine method
(Sakurada et al., 1978
) with the following modification; the
[14C]IAP (40 µCi in 0.8 ml of physiological
saline) was administered by a programmed intravenous infusion that
produced a nearly linear rise in arterial tracer concentration
throughout the period of measurement of CBF (Adachi et al., 1994
).
Throughout the approximately 1-min period of infusion, timed arterial
blood samples were collected on weighed filter paper discs, which were
assayed later for their [14C]IAP concentrations
by liquid scintillation counting, as previously described (Sakurada et
al., 1978
). At a precisely recorded time, approximately 1 min after
onset of the infusion of [14C]IAP, the rat was
decapitated, and the brain was rapidly removed, frozen in isopentane
maintained at
40o to
50°C with dry ice, and
cut into 20-µm sections in a cryostat at
22°C. The frozen brain
sections were thaw-mounted on glass cover-slips, immediately dried on a
hot plate at about 60°C, and autoradiographed together with
calibrated [14C]methylmethacrylate standards on
Kodak EMC-1 X-ray film (Eastman Kodak, Rochester, NY). Local tissue
concentrations of [14C]IAP were determined by
densitometric analysis of the autoradiograms. Rates of local CBF were
calculated from the local tissue concentrations and the time course of
the arterial [14C]IAP concentration by means of
the operational equation of the method (Sakurada et al., 1978
) and the
computer program developed by G. Mies (Max Planck Institut für
Neurologische Forschung, Köln, Germany) for use with the NIH
Image program (W. Rasband; National Institute of Mental Health,
Bethesda, MD) and a Macintosh computer (Apple Computer, Cupertino, CA).
Corrections for delay and dispersion in the arterial catheter sampling
system were incorporated in the computation of blood flow, as
previously described (Freygang and Sokoloff, 1958
), although the
magnitude of these corrections was reduced to almost negligible levels
by adjusting the blood flow through the arterial sampling system to
approximately 60 dead-space volumes/min.
Statistical Analyses
Values of local CBF in the structures of the whisker-to-barrel cortex pathway of the stimulated and unstimulated sides of the brain were statistically compared by paired t tests. The effects of haloperidol on physiological variables, absolute values of local CBF, and the logarithm of the percent stimulation of CBF by functional activation were evaluated for statistical significance by unpaired t tests. If statistically significant effects (p < 0.05) were found by the t tests, Bonferroni corrections for multiple comparisons were applied where appropriate.
| |
Results |
|---|
|
|
|---|
Behavior.
All of the haloperidol-treated rats exhibited
dose-dependent signs of catalepsy. The degree of catalepsy was
evaluated according to the scale described by Pizzolato et al. (1984)
,
which ranges from 0 (no effect) to 4 (completely cataleptic) on the
basis of the following features: presence and intensity of reduced
spontaneous movements of head and forelimbs; hypertonic-akinetic
posture with kyphotic trunk, extended head, broad-based support, and
rigid up-turned tail; resistance to imposed horizontal displacement of
forequarters; and ptosis. Rats given the low dose of haloperidol fell
in the 1 to 2 range, and those given the high dose fell within the 3 to
4 range. The behavioral effects appeared shortly after haloperidol
administration and persisted throughout the measurement of CBF.
Physiological Variables.
There were no statistically
significant differences in arterial blood pCO2,
pO2, pH, arterial plasma glucose concentration, and mean arterial blood pressure between either of the
haloperidol-treated groups and their corresponding controls (Table
1). Arterial blood pO2 levels and arterial plasma glucose
concentrations were higher in the rats receiving 1.0 mg/kg haloperidol
than in those receiving 0.1 mg/kg, but these differences probably
resulted from the lower pH of the vehicle for the higher dose because
these differences were also present and statistically significant in
the vehicle-treated controls (p < 0.02 and
p < 0.002, respectively) (Table 1).
|
Effects of Haloperidol on Local CBF in Representative Cerebral
Structures Unrelated to the Whisker-to-Barrel Cortex Sensory
Pathway.
The 0.1-mg/kg dose of haloperidol had no statistically
significant effects on CBF in any of the structures outside the
whisker-to-barrel cortex pathway examined. By standard t
tests, the 1.0-mg/kg dose statistically significantly lowered CBF in
the frontal (p < 0.05) and visual (p < 0.05) cortices, hippocampus (p < 0.05), dentate gyrus (p < 0.05), inferior olive (p < 0.01), and cerebellar cortex (p<0.05), and increased CBF in
the lateral habenula (p < 0.01), but all of these
changes lost statistical significance after Bonferroni corrections for
multiple comparisons (Table 2).
|
Effects of Haloperidol on CBF Responses to Vibrissal
Stimulation.
The effects of haloperidol on baseline levels of
local CBF were determined not only from its effects in structures
outside the whisker-to-barrel cortex sensory pathway (Table 2) but also from its effects on CBF in the unstimulated side of the structures within the pathway. The effects of vibrissal stimulation on local CBF
were determined by side-to-side comparisons between the stimulated and
unstimulated sides in the structures of the whisker-to-barrel cortex
pathway. As in the structures outside the pathway, the 0.1-mg/kg dose
of haloperidol had no statistically significant effects on baseline CBF
in the unstimulated side. Neither did it have any effect on the
magnitude of the enhancement of CBF by vibrissal stimulation. Of the
four structures of the pathway examined, the 1.0-mg/kg dose lowered
baseline CBF statistically significantly (p < 0.01)
only in the VPM thalamic nucleus by standard t tests and not
after Bonferroni correction for multiple comparisons. The 1.0-mg/kg
dose did, however, statistically significantly enhance the percent
increases in CBF due to the vibrissal stimulation in the spinal
trigeminal nucleus (p < 0.006) and VPM thalamic nucleus
(p < 0.004) but not in the principal sensory
trigeminal nucleus and barrel cortex, and these changes retained
statistical significance even after
correction for multiple comparisons
(p < 0.05) (Figs. 1 and
2).
|
|
| |
Discussion |
|---|
|
|
|---|
There is considerable evidence of dopaminergic innervation and
effects of dopamine on blood vessels, including those in the brain.
Some of these effects appear to be mediated by specific dopamine
receptors because they can be blocked by dopamine antagonists (Goldberg, 1972
, 1975
; von Essen and Roos, 1974
; Toda, 1976
; Boullin et
al., 1977
; Edvinsson et al., 1977
, 1978
; McCulloch and Harper, 1977
;
Krimer et al., 1998
). On the basis of these observations, it was
hypothesized that dopaminergic mechanisms might be involved in the
normal regulation of CBF and, more particularly, in its enhancement by
neuronal functional activation (Krimer et al., 1998
). In the present
studies, which were undertaken to test this hypothesis, the effects of
blockade of dopamine receptors on the increases in local CBF evoked by
functional activation of a sensory pathway were examined. In view of
the uncertainty about which of the several dopamine receptors might be
involved in such mechanisms, the dopamine antagonist haloperidol was
chosen because of its relatively low receptor specificity. To
compensate for quantitative differences in the affinity of haloperidol
for the various receptors, low and high doses of haloperidol were used
to cover the range of doses previously shown to alter glucose
utilization in cerebral structures known to be components of
dopaminergic pathways and to be rich in dopaminergic receptors
(McCulloch et al., 1980
, 1982
)
The low dose of haloperidol (0.1 mg/kg) had no statistically
significant effects on baseline CBF in any of the 30 structures examined; nor did it alter the percent increases in CBF in the four
structures of the whisker-to-barrel cortex pathway evoked by vibrissal
stimulation. The high dose of haloperidol (1.0 mg/kg) did alter
baseline CBF statistically significantly in the VPM thalamic nucleus
and in several structures of the brain outside the whisker-to-barrel
cortex pathway (i.e., reduced baseline CBF in the frontal and visual
cortices, hippocampus, dentate gyrus, inferior olive, and cerebellar
cortex, and increased CBF in the lateral habenula), but these changes
lost statistical significance after Bonferroni corrections for multiple
comparisons. Bonferroni statistics, however, are notoriously
conservative and prone to type II errors, which might possibly have
obscured a tendency for small selective local effects on CBF by
haloperidol. For example, in the six structures outside the
whisker-to-barrel cortex pathway in which the uncorrected t
tests showed statistically significant lowering of CBF by the high dose
of haloperidol, all but the inferior olive had been reported to exhibit
significant reductions in local glucose utilization after
administration of the same dose of haloperidol; glucose utilization in
the VPM thalamic nucleus was not reported but found to be reduced in
other parts of the thalamus (McCulloch et al., 1980
, 1982
; Pizzolato et
al., 1984
, 1985
). There were a few discrepancies. For example,
haloperidol was reported to reduce glucose utilization in the parietal
cortex, medial geniculate, and hypothalamus (McCulloch et al., 1980
,
1982
; Pizzolato et al., 1984
, 1985
), but even by the uncorrected
t tests, it had no statistically significant effects on CBF
in these structures. Also, the lateral habenula and the nucleus
accumbens are two of the very few reported to show increased glucose
utilization in response to 1.0 mg/kg haloperidol (McCulloch et al.,
1980
, 1982
; Pizzolato et al., 1984
, 1985
), and both showed increases in
CBF in the present study, although the lateral habenula was the only
structure in which the uncorrected t test showed haloperidol
to cause a statistically significant increase in CBF. This tendency for
corresponding changes in both CBF and glucose metabolism in a number of
structures suggests that haloperidol might have some effects on local
CBF, but they are likely to be secondary to changes in energy
metabolism rather than to inhibition of direct vasoactive actions of
dopamine at the level of dopamine receptors on the cerebral blood
vessels. Such an interpretation is consistent with that of McCulloch
and Harper (1977)
, who found hemispheric CBF and oxygen consumption to
rise and then decline in parallel following apomorphine administration and both effects to be blocked by the neuroleptic pimozide; they also
concluded that the blood flow changes were secondary to the effects of
apomorphine on energy metabolism.
A major purpose of the present study was to evaluate the possibility
that the augmentation of CBF by neuronal functional activation was
mediated by vasoactive actions of dopamine. As previously observed
(Ginsberg et al., 1987
; Adachi et al., 1994
), unilateral vibrissal
stimulation markedly raised blood flow in all stations of the pathway
on the stimulated side, i.e., the spinal and principal trigeminal
nuclei in the brain stem, the VPM nucleus of the thalamus, and the
barrel region of the sensory cortex. Blockade of dopamine receptors
with doses of haloperidol sufficient to produce profound behavioral
effects and to reduce blood flow in some regions of the brain failed to
abolish or even to reduce the enhancement of blood flow by functional
activation in any of the stations of the pathway. In fact, in the
spinal trigeminal nucleus and VPM thalamic nucleus, the high dose of
haloperidol statistically significantly increased rather than decreased
the percent enhancement of CBF due to vibrissal stimulation. These
results, therefore, fail to support a role for dopaminergic mechanisms
in the functional activation of local CBF, at least not in the
whisker-to-barrel cortex pathway, a representative sensory pathway
often used to study the circulatory and metabolic responses to neuronal
functional activation.
| |
Footnotes |
|---|
Accepted for publication July 3, 2002.
Received for publication May 22, 2002.
DOI: 10.1124/jpet.102.039081
Address correspondence to: Dr. Louis Sokoloff, Laboratory of Cerebral Metabolism, National Institute of Mental Health, Building No. 36, 1A-07, 36 Convent Drive MSC 4030, Bethesda, MD 20892-4030. E-mail: louis{at}shiloh.nimh.nih.gov
| |
Abbreviations |
|---|
CBF, cerebral blood flow; [14C]IAP, 4-iodo[N-methyl-14C]antipyrine; VPM, ventral posteromedial.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. M. Landau, R. Lal, J. P. O'Neil, S. Baker, and W. J. Jagust Striatal Dopamine and Working Memory Cereb Cortex, February 1, 2009; 19(2): 445 - 454. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||